Cerebrospinal fluid biomarkers in Alzheimer disease a fractional improvement?

被引：9

作者：

Galasko, D

机构：

[1] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92161 USA

[2] VA Med Ctr, Serv Neurol, San Diego, CA 92161 USA

来源：

ARCHIVES OF NEUROLOGY | 2003年 / 60卷 / 09期

关键词：

D O I：

10.1001/archneur.60.9.1195

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1195 / 1196

页数：2

共 10 条

[1] Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments [J].

Barghorn, S ;

Mandelkow, E .

BIOCHEMISTRY, 2002, 41 (50) :14885-14896

[2] Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].

Buerger, K ;

Zinkowski, R ;

Teipel, SJ ;

Tapiola, T ;

Arai, H ;

Blennow, K ;

Andreasen, N ;

Hofmann-Kiefer, K ;

DeBernardis, J ;

Kerkman, D ;

McCulloch, C ;

Kohnken, R ;

Padberg, F ;

Pirttilä, T ;

Schapiro, MB ;

Rapoport, SI ;

Möller, HJ ;

Davies, P ;

Hampel, H .

ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272

[3] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].

Galasko, D ;

Chang, L ;

Motter, R ;

Clark, CM ;

Kaye, J ;

Knopman, D ;

Thomas, R ;

Kholodenko, D ;

Schenk, D ;

Lieberburg, I ;

Miller, B ;

Green, R ;

Basherad, R ;

Kertiles, L ;

Boss, MA ;

Seubert, P .

ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945

[4] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[5] Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease [J].

Itoh, N ;

Arai, H ;

Urakami, K ;

Ishiguro, K ;

Ohno, H ;

Hampel, H ;

Buerger, K ;

Wiltfang, J ;

Otto, M ;

Kretzschmar, H ;

Moeller, HJ ;

Imagawa, M ;

Kohno, H ;

Nakashima, K ;

Kuzuhara, S ;

Sasaki, H ;

Imahori, K .

ANNALS OF NEUROLOGY, 2001, 50 (02) :150-156

[6] Practice parameter: Diagnosis of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].

Knopman, DS ;

DeKosky, ST ;

Cummings, JL ;

Chui, H ;

Corey-Bloom, J ;

Relkin, N ;

Small, GW ;

Miller, B ;

Stevens, JC .

NEUROLOGY, 2001, 56 (09) :1143-1153

[7] Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42 [J].

Maddalena, A ;

Papassotiropoulos, A ;

Müller-Tillmanns, B ;

Jung, HH ;

Hegi, T ;

Nitsch, RM ;

Hock, C .

ARCHIVES OF NEUROLOGY, 2003, 60 (09) :1202-1206

[8] Mild cognitive impairment - Clinical characterization and outcome [J].

Petersen, RC ;

Smith, GE ;

Waring, SC ;

Ivnik, RJ ;

Tangalos, EG ;

Kokmen, E .

ARCHIVES OF NEUROLOGY, 1999, 56 (03) :303-308

[9] Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment [J].

Riemenschneider, M ;

Lautenschlager, N ;

Wagenpfeil, S ;

Diehl, J ;

Drzezga, A ;

Kurz, A .

ARCHIVES OF NEUROLOGY, 2002, 59 (11) :1729-1734

[10] Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid:: a sandwich ELISA with a synthetic phosphopeptide for standardization [J].

Vanmechelen, E ;

Vanderstichele, H ;

Davidsson, P ;

Van Kerschaver, E ;

Van Der Perre, B ;

Sjögren, M ;

Andreasen, N ;

Blennow, K .

NEUROSCIENCE LETTERS, 2000, 285 (01) :49-52

← 1 →